[Clinical efficiency of candesatran depends on angiotension II receptor, type 1 gene polymorphism].
Frequency of A and C alleles of the polymorphic gene (A1166C) of first type angiotension II receptor in healthy men of Poltava region was 68% and 32% accordingly, the AA, AC and CC genotypes made up 51%,34% and 15% correspondingly. The patients with essential hypertension had the following figures: 44% and 56%; 23%, 52% and 25% accordingly. The presence of C allele has been established to lead to more severe course and an early development of essential hypertension. Candesatran monoterapy is more effective for treatment patients having C allele.
Kaĭdashev
I P
IP
Rasin
M S
MS
Savchenko
L G
LG
Shlykova
O A
OA
Iakimishina
L I
LI
D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D001794:Blood Pressure / Q000187:drug effects*; D004247:DNA / Q000032:analysis; D005787:Gene Frequency; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012150:Polymorphism, Restriction Fragment Length; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics*; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014455:Ukraine
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D004247:DNA; C081643:candesartan